Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNTI Senti Biosciences, Inc.

Pre-Mkt 08-04 07:14:29 EDT

0.3701

+0.0296

+8.69%

High0.3898	Low0.3501	Vol137.55K
Open0.3509	D1 Closing0.3405	Amplitude11.66%
Mkt Cap11.53M	Tradable Cap5.40M	Total Shares31.14M
T/O50.85K	T/O Rate0.94%	Tradable Shares14.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNTI","market":"US","secType":"STK","nameCN":"Senti Biosciences, Inc.","latestPrice":0.3701,"timestamp":1785787200000,"preClose":0.3405,"halted":0,"volume":137550,"delay":0,"changeRate":0.08693098384728329,"floatShares":14577400,"shares":31144500,"eps":-1.9197,"marketStatus":"Pre-Mkt","change":0.0296,"latestTime":"08-04 07:14:29 EDT","open":0.3509,"high":0.389799,"low":0.3501,"amount":50851.962651,"amplitude":0.11659,"askPrice":0.4342,"askSize":100,"bidPrice":0.34,"bidSize":208,"shortable":3,"etf":0,"ttmEps":-1.9197,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785850200000},"marketStatusCode":1,"adr":0,"listingDate":1622001600000,"exchange":"NASDAQ","adjPreClose":0.3701,"postHourTrading":{"tag":"盘后","latestPrice":0.3701,"preClose":0.3701,"latestTime":"19:20 EDT","volume":63,"amount":23.5527,"timestamp":1785799243164,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5563645188015575},"requestUrl":"/m/hq/s/SNTI/wiki","defaultTab":"wiki","newsList":[{"id":"2651468895","title":"Senti Bio announces transaction to spin off Gene-Circuit-enabled pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2651468895","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651468895?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:00","pubTimestamp":1784116828,"startTime":"0","endTime":"0","summary":"Senti Bio (SNTI) announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/senti-bio-announces-transaction-to-spin-off-gene-circuit-enabled-pipeline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/senti-bio-announces-transaction-to-spin-off-gene-circuit-enabled-pipeline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450838","title":"Senti Biosciences to Spin Off Senti-202 Assets to Celadon-backed Newco for CVR Worth up to $60 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450838","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450838?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:31","pubTimestamp":1784115063,"startTime":"0","endTime":"0","summary":"Senti Biosciences to spin off SENTI-202 assets to Celadon-backed NewCo for CVR worth up to $60 millionCeladon-controlled NewCo to acquire Senti Biosciences Holdings’ Gene-Circuit pipeline assets, incl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL1GDn47:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4539","SG9999014013.SGD","LU0314104364.USD","BK4588","SG9999014039.USD","NDAQ","BCDF","LU2210150020.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4112","SNTI","IE00BN0W2V16.EUR","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651457700","title":"Senti Biosciences - CVR Milestones: $10 Mln for Bla Filing, $20 Mln for FDA Approval, $30 Mln for $200 Mln Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651457700?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:30","pubTimestamp":1784115011,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0VO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145705","title":"Senti Biosciences - Newco to Buy Gene-circuit Pipeline Including Senti-202 for CVR up to $60 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651145705?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:30","pubTimestamp":1784115011,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0VO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450849","title":"Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450849","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450849?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:30","pubTimestamp":1784115000,"startTime":"0","endTime":"0","summary":"Senti Biosciences Holdings, Inc. to Advance Controllable Cell and Gene Therapies Leveraging the Regulator Dial PlatformSpin-off of Senti Biosciences, Inc., including SENTI-202, Aims to Unlock Value vi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/15/3327605/0/en/Senti-Biosciences-Holdings-Inc-Announces-a-Strategic-Transaction-to-Unlock-Value-for-its-Gene-Circuit-Enabled-Pipeline-Including-SENTI-202-and-to-Sharpen-its-Focus-on-Next-Generati.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SYNB","MDCO","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651457497","title":"NASDAQ Trade Halt Halt News Pending at 07:25 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2651457497","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651457497?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:25","pubTimestamp":1784114700,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:25 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nAQN2M82CO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644034646","title":"BRIEF-Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2644034646","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644034646?lang=en_us&edition=fundamental","pubTime":"2026-06-19 06:37","pubTimestamp":1781822228,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder June 18  - Senti Biosciences Holdings Inc SNTI.O:OFFERING 15.97 MILLION SHARES OF COMMON STOCK FOR RESALE BY SELLING SECURITYHOLDER - SEC FILINGSource text: [ID:n0001193125-26-276079]Further company coverage: SNTI.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644397170","title":"Senti Biosciences - Offering 15.97 Mln Shares of Common Stock for Resale by Selling Securityholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644397170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644397170?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:06","pubTimestamp":1781816775,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540320","title":"Senti Biosciences unit issues USD 10 million senior secured convertible notes to Celadon Partners SPV 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540320?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:03","pubTimestamp":1779825793,"startTime":"0","endTime":"0","summary":"Senti Biosciences Holdings’ subsidiary Senti Holdings sold USD 10 million of Senior Secured Convertible Notes to Celadon Partners SPV 24 on May 20, 2026.Acquiom Agency Services was appointed collateral agent for the notes in connection with the May 20 issuance.Senti entered registration rights, guarantee, and voting agreements tied to the financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL70WXVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636969018","title":"Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636969018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636969018?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:40","pubTimestamp":1779036031,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-senti-biosciences-snti-alx-oncology-holdings-alxo-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-senti-biosciences-snti-alx-oncology-holdings-alxo-and-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","LU0889565916.HKD","LU1983260115.SGD","LU2324357040.USD","IE00B4R5TH58.HKD","BK4139","BK4581","XLV","LABU","XBI","IE0002141913.USD","BK4231","LU0128526141.USD","ARGX","BK4080","LU0320765992.SGD","BK4585","LU0029874061.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","SNTI","ALXO","IE0009355771.USD","IE00BJT1NW94.SGD","BK4588","BK4137","ALX","IE0034235188.USD","BK4505","BK4539","LU0109394709.USD","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635057876","title":"Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2635057876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635057876?lang=en_us&edition=fundamental","pubTime":"2026-05-16 14:00","pubTimestamp":1778911225,"startTime":"0","endTime":"0","summary":"Senti Biosciences, Inc. (SNTI) has disclosed a new risk, in the Debt & Financing category. Senti Biosciences, Inc. faces considerable refinancing a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908428","title":"Senti Biosciences Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635908428?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:27","pubTimestamp":1778848020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNTI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 08:27 ET (12:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635081089","title":"Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635081089","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635081089?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:05","pubTimestamp":1778846737,"startTime":"0","endTime":"0","summary":"Chardan Raises Price Target on Senti Biosciences to $12 From $11, Keeps Buy Rating","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710552","title":"Senti Biosciences Q1 net loss narrows on cost reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710552","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710552?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:54","pubTimestamp":1778763295,"startTime":"0","endTime":"0","summary":"Senti Biosciences Q1 net loss narrows on cost reductionOverviewUS biotechnology firm's Q1 revenue beat analyst expectationsNet loss narrowed yr/yr, aided by $6.9 mln gain from lease modificationOutloo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0NX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635271037","title":"BRIEF-Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635271037","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635271037?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:51","pubTimestamp":1778763086,"startTime":"0","endTime":"0","summary":"BRIEF-Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy May 14 (Reuters) - Senti Biosciences Holdings Inc SNTI.O:SENTI BIOSCIENCES HOLDINGS ANN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1XZZXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SNTI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635103217","title":"Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K","url":"https://stock-news.laohu8.com/highlight/detail?id=2635103217","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635103217?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:46","pubTimestamp":1778762808,"startTime":"0","endTime":"0","summary":"Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.36) by 61.11 percent. This is a 90.07 percent increase over losses of $(1.41) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52558096/senti-biosciences-q1-eps-0-14-beats-0-36-estimate-sales-16-000k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710317","title":"Senti Biosciences Holdings Inc: Q1 Net Loss per Share $0.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710317?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:45","pubTimestamp":1778762700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX590F4A:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710850","title":"Press Release: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710850","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710850?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:45","pubTimestamp":1778762700,"startTime":"0","endTime":"0","summary":"Secured strategic financing vehicle for up to $40 million. Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn. SOUTH SAN FRANCISCO, Calif., May 14, 2026  -- Senti Biosciences Holdings, Inc.  , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.In addition, Senti announced that it identified a specific Donor X attribute that correlates with efficacy of SENTI-202, with 50%  of the patients achieving a composite CR  when they received any SENTI-202 doses manufactured from Donor X-characteristic derived NK cells in Cycle 1. The Donor X attribute is found in 50% of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4585","LU2746668461.USD","BK4139","LU2237443622.USD","BK4183","LU2746668974.SGD","SNTI","IE0009354923.USD","LU2237443465.HKD","LU2237443895.HKD","BK4006","LU2237443382.USD","IE00BHPRN162.USD","IE00B1BXHZ80.USD","LU0149725797.USD","BK4539","LU1363072403.SGD","LABU","IE00BFXG1179.USD","CMC","LU0170899867.USD","LU2237443978.SGD","BK4588","LU0267386448.USD","ODD","LU0971096721.USD","LU2237443549.SGD","IE00BZ1G4Q59.USD","LU0882574139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771740","title":"Senti Biosciences Holdings Announces Positive FDA Rmat Meeting on Registrational Clinical and Cmc Strategy for Senti-202 in Relapsed/Refractory Aml, Along With Important Efficacy and Durability Updates on the Senti-202 Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635771740?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:40","pubTimestamp":1778762400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1XZZXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNTI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717201","title":"Senti Biosciences Holdings Inc - Senti-202 Future Manufacturing to Use Donor X Phenotype","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717201?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:40","pubTimestamp":1778762400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA1XZZXK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","SNTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sentibio.com","stockEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.6541},{"period":"3month","weight":-0.6121},{"period":"6month","weight":-0.5888},{"period":"1year","weight":-0.7797},{"period":"ytd","weight":-0.6441}],"compareEarnings":[{"period":"1week","weight":0.0251},{"period":"1month","weight":0.0173},{"period":"3month","weight":0.0468},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2187},{"period":"ytd","weight":0.1111}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.037903},{"month":2,"riseRate":0.2,"avgChangeRate":-0.117173},{"month":3,"riseRate":0.2,"avgChangeRate":-0.07377},{"month":4,"riseRate":0.4,"avgChangeRate":-0.016933},{"month":5,"riseRate":0.4,"avgChangeRate":-0.057207},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.225173},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.015033},{"month":8,"riseRate":0.5,"avgChangeRate":-0.085465},{"month":9,"riseRate":0.4,"avgChangeRate":-0.088688},{"month":10,"riseRate":0.6,"avgChangeRate":0.032318},{"month":11,"riseRate":0.4,"avgChangeRate":0.12033},{"month":12,"riseRate":0.4,"avgChangeRate":0.047383}],"exchange":"NASDAQ","name":"Senti Biosciences, Inc.","nameEN":"Senti Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Senti Biosciences, Inc.,SNTI,Senti Biosciences, Inc.股票,Senti Biosciences, Inc.股票老虎,Senti Biosciences, Inc.股票老虎国际,Senti Biosciences, Inc.行情,Senti Biosciences, Inc.股票行情,Senti Biosciences, Inc.股价,Senti Biosciences, Inc.股市,Senti Biosciences, Inc.股票价格,Senti Biosciences, Inc.股票交易,Senti Biosciences, Inc.股票购买,Senti Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Senti Biosciences, Inc.(SNTI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Senti Biosciences, Inc.(SNTI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}